AZD8330 is primarily investigated for its potential in cancer therapy. It functions as a MEK inhibitor, targeting the MAPK/ERK pathway, which is often dysregulated in various cancers. By inhibiting this pathway, AZD8330 can suppress tumor growth and proliferation. It is being explored in clinical trials for its efficacy in treating solid tumors, particularly those resistant to other therapies. Additionally, its role in combination treatments with other anticancer agents is under study to enhance therapeutic outcomes and overcome drug resistance.